I'm working in...
Arrow for button
Cross Arrow

I'm working in...

Role
Company
Select
Gray and White Background With Curved Elements
Bristol Myers Squibb

BMS Adopts a New Clinical Data Architecture

Glowing dots and lines

Facing an increase in data volume and diversity, BMS began adopting eClinical Solutions’ elluminate Clinical Data Cloud®, Mapper and Clinical Analytics. Initially, they piloted the solution with five early studies that had no critical database lock or analysis milestones, and which contained less data than their larger phase three trials.

Industry
Pharmaceuticals
Number of Employees
30,000+
Corporate HQ
Princeton, New Jersey

Challenge

Bristol Myers Squibb wanted to optimize their data review processes to streamline and improve access to their data. The need to build forms, store huge volumes of data in Medidata Rave and migrate them with post-production changes increased the load on the EDC system.

They wanted to find a complementary solution that would integrate with, and support, Medidata Rave, as well as provide streamlined, governed access to a broad set of clinical data, and to support data curation and data aggregation, enabling generations of insights to advance clinical development.

Solution

elluminate Solution Highlights

  1. Single access point for all clinical data sources
  2. Robust analytics capabilities
  3. Quicker access to accurate data for end-users

BMS streamlined their clinical data flow with elluminate’s importer module for quicker access to clean data, and Mapper for their Consolidated Clinical Views (CCVs). The team is now able to dedicate their time to more productive data tasks like analysis. elluminate has enabled complete visibility into who has access to the data and into the lifecycle of the data, which is vital for clinical trial approvals.

Result

BMS has found great success with elluminate in alleviating the pain points in their previous infrastructure. The platform will continue to compile all data sources into a unified source of data, while creating cross-study analytics reports and enabling deeper insights.

Stage two of BMS’s implementation involves all non-CRF data being imported directly into elluminate. Using elluminate, consolidated clinical data can be easily exported for downstream consumption, which includes areas such as the biostatistics department and other reporting platforms that are used at BMS.

How We Helped

Related Products + Services

BMS enhanced their data management through Data Conversion and Standardization, streamlining processes and improving access. They adopted eClinical Solutions’ elluminate, consolidating data sources and enabling cross-study analytics for deeper insights amidst growing data volume and diversity.

mapper icons
data central icon
analytics icon
Karyopharm
Karyopharm

Mapper

Powerful data transformation, unification and automation from diverse data sources and formats without programming for submission and analytic needs.

Learn More

mapper icons

Data Central

All your trial data from every source, one place for integrated review- listings, patient profiles, analytics, queries and issue management.

Learn More

data central icon

Clinical Analytics

Comprehensive visualizations and reporting that support safety and efficacy decisions within and across trials, operational analytics that help proactively manage your trial.

Learn More

analytics icon

Biometrics Services

Tech-enabled approach to shorten submission timelines and improved ability to support real-time creation of “submission ready” datasets.

Learn More

Karyopharm

elluminate Implementation

Customized implementation services are based on your organizational data strategy and needs to ensure business transformation and ROI.

Learn More

Karyopharm

2024 Industry Outlook: Driving Tomorrow’s Breakthroughs with Clinical Data Transformation

X